SCHEMBL23744715

SCHEMBL23744715

C[C@@H]1CN(c2nc3cc(F)c(F)cc3s2)C[C@H](C)N1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 11/20 0.40
NPC1 O15118 11/20 0.40
SMN1; SMN2 Q16637 10/20 0.40
ALDH1A1 P00352 6/20 0.40
TP53 P04637 7/20 0.36
MITF O75030 1/20 0.36
NFKB1 P19838 1/20 0.36
NFKB2 Q00653 1/20 0.36
RELA Q04206 1/20 0.36
MAPT P10636 6/20 0.36
HPGD P15428 3/20 0.36
HSD17B10 Q99714 3/20 0.36
USP2 O75604 2/20 0.36
ALOX15 P16050 2/20 0.36
LMNA P02545 2/20 0.36
PKM P14618 1/20 0.36
MAPK1 P28482 1/20 0.36
NAAA Q02083 1/20 0.36
GAA P10253 1/20 0.35
TSHR P16473 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23744730 1.00 RAB9A (0.40) RAB9ANPC1SMN1; SMN2ALDH1A1TP53
SCHEMBL30345677 1.00 RAB9A (0.40) RAB9ANPC1SMN1; SMN2ALDH1A1TP53
SCHEMBL30345599 1.00 RAB9A (0.40) RAB9ANPC1SMN1; SMN2ALDH1A1TP53
SCHEMBL10271172 0.91 ILK (0.41) RAB9ANPC1SMN1; SMN2ALDH1A1TP53
SCHEMBL10219245 0.87 NPC1 (0.36) RAB9ANPC1SMN1; SMN2ALDH1A1TP53
SCHEMBL23744769 0.83 NPC1 (0.36) RAB9ANPC1SMN1; SMN2ALDH1A1TP53
SCHEMBL23744366 0.83 NPC1 (0.48) RAB9ANPC1SMN1; SMN2ALDH1A1TP53
SCHEMBL23744758 0.83 NPC1 (0.62) RAB9ANPC1SMN1; SMN2ALDH1A1TP53
SCHEMBL19617845 0.83 NPC1 (0.62) RAB9ANPC1SMN1; SMN2ALDH1A1TP53
SCHEMBL23744759 0.83 NPC1 (0.62) RAB9ANPC1SMN1; SMN2ALDH1A1TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4100410-B1 MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE NEUROCRINE BIOSCIENCES INC (US) 2026-04-22 EP disclosed
US-20230129359-A1 MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE NEUROCRINE BIOSCIENCES, INC. 2023-04-27 US disclosed
US-20230129359-A1 MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE NEUROCRINE BIOSCIENCES, INC. 2023-04-27 US disclosed
US-20230129359-A1 MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE NEUROCRINE BIOSCIENCES, INC. 2023-04-27 US disclosed
WO-2021158698-A1 MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE NEUROCRINE BIOSCIENCES, INC. (US) 2021-08-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230129359-A1 MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE CHRM4, CHRM2, CHRM5 RAB9A 3190/4885NPC1 1236/4885SMN1; SMN2 1135/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.